Printer Friendly

ALPHA 1 BIOMEDICALS ANNOUNCES SECOND QUARTER CALENDAR YEAR 1992 RESULTS

ALPHA 1 BIOMEDICALS ANNOUNCES SECOND QUARTER CALENDAR YEAR 1992 RESULTS
 BETHESDA, Md., Aug. 7 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) today reported financial results for the second quarter of calendar year 1992.
 Revenues for the second quarter were $56,299 and expenses were $1,031,244 resulting in a net loss of $974,945 or 13 cents per share. The results for the same quarter of the preceding year were $37,096 in revenues, $746,283 in expenses and a loss of $709,187 or 12 cents per share.
 For the first six months, revenues of $117,140 and expenses of $2,019,416 resulted in a loss of $1,902,276 or 26 cents per share. The results for the comparable period a year earlier were revenues of $61,628 and expenses of $1,444,642 for a loss of $1,383,014 or 23 cents per share.
 Reported losses for the quarter and six month period were in line with management's expectations and are primarily associated with expenses of ongoing clinical trials and operating costs.
 The company's product inventory has increased this calendar year to accommodate orders received from its foreign licensees. In this regard, the company has received more than $250,000 in advance payments, which have been recorded as unearned revenue. The company anticipates revenue from these orders during the current calendar year when Thymosin alpha 1 is exported.
 Alpha 1 Biomedicals, Inc. is a Bethesda-based company engaged in the development of pharmaceutical products.
 ALPHA 1 BIOMEDICALS, INC.
 (Unaudited)
 Periods ended Three months Six months
 June 30 1992 1991 1992 1991
 Revenue $ 56,299 $ 37,096 $ 117,140 $ 61,628
 Expenses 1,031,244 746,283 2,019,416 1,444,642
 Net loss 974,945 709,187 1,902,276 1,383,014
 Net loss per common share $.13 $.12 $.26 $.23
 Weighted average common
 shares outstanding 7,326,217 6,021,212 7,307,824 5,940,467
 -0- 8/7/92
 /CONTACT: R. J. Lanham, vice president-finance and administration of Alpha 1 Biomedicals, 301-564-4400, or Anita Monteith Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM) CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: ERN


SB-TS -- NY007 -- 7909 08/07/92 09:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 7, 1992
Words:376
Previous Article:PEACH BOTTOM HOSTS JAPANESE EXCHANGE VISITORS
Next Article:DEVRY REPORTS SUMMER TERM ENROLLMENT INCREASES
Topics:


Related Articles
ALPHA 1 BIOMEDICALS ANNOUNCES SECOND QUARTER CALENDAR YEAR 1992 RESULTS
ICN BIOMEDICALS REPORTS THIRD CONSECUTIVE QUARTER OF PROFITABILITY; DEBT SIGNIFICANTLY REDUCED
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES FOURTH QUARTER AND CALENDAR YEAR 1993 RESULTS
ICN BIOMEDICALS REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
ALPHA 1 BIOMEDICALS, INC. REPORTS SECOND QUARTER CALENDAR YEAR 1994 RESULTS
ALPHA I BIOMEDICALS, INC. FIRST QUARTER CALENDAR YEAR 1995 RESULTS
ALPHA 1 BIOMEDICALS, INC. SECOND QUARTER CALENDAR YEAR 1995 RESULTS
ALPHA 1 BIOMEDICALS, INC. THIRD QUARTER CALENDAR YEAR 1995 RESULTS
ALPHA 1 BIOMEDICALS, INC. REPORTS FIRST QUARTER CALENDAR YEAR 1996 RESULTS
Alpha 1 Biomedicals, Inc. First Quarter Calendar Year 1997 Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters